Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).

被引：1
|
作者：
Miura, Satoru
Hsia, Te-Chun
Hung, Jen-Yu
Jung, Hyun Ae
Shih, Jin-Yuan
Park, Cheol-Kyu
Lee, Seung Hyeun
Okamoto, Tatsuro
Ahn, Hee Kyung
Lee, Yong Chul
Sato, Yuki
Lee, Sung Sook
Mascaux, Celine
Daoud, Hasan
Maerten, Angela
Popat, Sanjay
机构：
[1] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
[2] China Med Univ, Dept Resp Therapy, China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[3] Kaohsiung Med Univ, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[5] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[6] Chonnam Natl Univ, Dept Internal Med, Hwasun Hosp, Hwasun, South Korea
[7] Kyung Hee Univ, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, Seoul, South Korea
[8] Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan
[9] Gachon Univ, Gil Med Ctr, Div Med Oncol, Incheon, South Korea
[10] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Dept Internal Med,Biomed Res Inst,Med Sch, Jeonju, South Korea
[11] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan
[12] Inje Univ, Coll Med, Haeundae Paik Hosp, Busan, South Korea
[13] Strasbourg Univ, Strasbourg Univ Hosp, Dept Pulm, Strasbourg, France
[14] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[15] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England
[16] Inst Canc Res, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9072
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9072
引用
收藏
页数：3
相关论文
共 50 条
  • [1] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
  • [2] A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
    Miura, S.
    Hsia, T.
    Hung, J.
    Jung, H. A.
    Shih, J.
    Park, C.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1115 - S1116
  • [3] Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
    Popat, Sanjay
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Park, Cheol Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Marten, Angela
    Miura, Satoru
    [J]. ONCOLOGIST, 2022, 27 (04): : 255 - 265
  • [4] Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs)
    Si, Jinfei
    Gu, Xiaodong
    Wang, Wenxian
    Ying, Shenpeng
    Song, Zhengbo
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (05) : 1624 - 1634
  • [5] Outcomes in Patients with Compound Epidermal Growth Factor Receptor (EGFR) Mutations After Treatment with Tyrosine Kinase Inhibitors (TKIs)
    Breslin, S.
    Thompson, J.
    Morrissette, J.
    Ciunci, C.
    Singh, A.
    Aggarwal, C.
    Cohen, R.
    Langer, C.
    Bauml, J.
    Marmarelis, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S839 - S839
  • [6] UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Yang, T-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S776 - S777
  • [7] Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
    Zhu, Lulin
    Yang, Xinxin
    Wu, Shanshan
    Dong, Rong
    Yan, Youyou
    Lin, Nengming
    Zhang, Bo
    Tan, Biqin
    [J]. DRUG METABOLISM REVIEWS, 2024,
  • [8] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Montanino, A.
    Rocco, G.
    Galetta, D.
    Montagna, S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, M. C.
    Perrone, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [9] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Rocco, G.
    Galetta, D.
    Montagna, E. S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, C.
    Perrone, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics
    van Zandwijk, N
    [J]. LUNG CANCER, 2006, 51 (01) : 137 - 138
12345